U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972472) titled 'A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes' on May 07.
Brief Summary: The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Type 2 Diabetes
Intervention:
DRUG: Orforglipron
Administered orally
DRUG: Placebo
Administered orally
Recruitment Status...